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Efficacy ofMindfulness-Based Cognitive Therapy
in Prevention of Depressive Relapse
An Individual Patient Data Meta-analysis
From Randomized Trials
Willem Kuyken, PhD; Fiona C. Warren, PhD; Rod S. Taylor, PhD; BenWhalley, PhD; Catherine Crane, PhD; Guido Bondolfi, MD, PhD; Rachel Hayes, PhD;
Marloes Huijbers, MSc; HelenMa, PhD; Susanne Schweizer, PhD; Zindel Segal, PhD; Anne Speckens, MD; John D. Teasdale, PhD;
Kees Van Heeringen, PhD; MarkWilliams, PhD; Sarah Byford, PhD; Richard Byng, PhD; Tim Dalgleish, PhD
IMPORTANCE Relapse prevention in recurrent depression is a significant public health
problem, and antidepressants are the current first-line treatment approach. Identifying an
equally efficacious nonpharmacological intervention would be an important development.
OBJECTIVE To conduct a meta-analysis on individual patient data to examine the efficacy of
mindfulness-based cognitive therapy (MBCT) compared with usual care and other active
treatments, including antidepressants, in treating those with recurrent depression.
DATA SOURCES English-language studies published or accepted for publication in
peer-reviewed journals identified from EMBASE, PubMed/Medline, PsycINFO,Web of
Science, Scopus, and the Cochrane Controlled Trials Register from the first available year to
November 22, 2014. Searches were conducted fromNovember 2010 to November 2014.
STUDY SELECTION Randomized trials of manualizedMBCT for relapse prevention in recurrent
depression in full or partial remission that comparedMBCTwith at least 1 non-MBCT
treatment, including usual care.
DATA EXTRACTION AND SYNTHESIS This was an update to a previousmeta-analysis. We
screened 2555 new records after removing duplicates. Abstracts were screened for full-text
extraction (S.S.) and checked by another researcher (T.D.). There were no disagreements. Of
the original 2555 studies, 766 were evaluated against full study inclusion criteria, and we
acquired full text for 8. Of these, 4 studies were excluded, and the remaining 4 were
combined with the 6 studies identified from the previous meta-analysis, yielding 10 studies
for qualitative synthesis. Full patient data were not available for 1 of these studies, resulting in
9 studies with individual patient data, which were included in the quantitative synthesis.
RESULTS Of the 1258 patients included, themean (SD) age was 47.1 (11.9) years, and 944
(75.0%) were female. A 2-stage random effects approach showed that patients receiving
MBCT had a reduced risk of depressive relapse within a 60-week follow-up period compared
with those who did not receive MBCT (hazard ratio, 0.69; 95% CI, 0.58-0.82). Furthermore,
comparisons with active treatments suggest a reduced risk of depressive relapse within a
60-week follow-up period (hazard ratio, 0.79; 95% CI, 0.64-0.97). Using a 1-stage approach,
sociodemographic (ie, age, sex, education, and relationship status) and psychiatric (ie, age at
onset and number of previous episodes of depression) variables showed no statistically
significant interaction with MBCT treatment. However, there was some evidence to suggest
that a greater severity of depressive symptoms prior to treatment was associated with a
larger effect of MBCT compared with other treatments.
CONCLUSIONS AND RELEVANCE Mindfulness-based cognitive therapy appears efficacious as a
treatment for relapse prevention for those with recurrent depression, particularly those with
more pronounced residual symptoms. Recommendations are made concerning how future
trials can address remaining uncertainties and improve the rigor of the field.
JAMA Psychiatry. 2016;73(6):565-574. doi:10.1001/jamapsychiatry.2016.0076
Published online April 27, 2016.
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A lthough progress has been made in the treatment ofmanypsychiatric conditions, recurrentdepressioncon-tinues tocause significantdisability andremainsahigh
cost to society.1,2 Interventions that prevent depressive re-
lapse among people at high risk of recurrent episodes have
significant potential to reduce the disease’s burden.3 Mind-
fulness-based cognitive therapy (MBCT), one such interven-
tion, teaches psychological skills that target cognitivemecha-
nisms implicated indepressive relapse topeoplewithahistory
of depression4 by combining systematic mindfulness train-
ing with elements from cognitive therapy. A systematic re-
viewandmeta-analysis5of6randomizedclinical trials (N = 593
patients) suggested that MBCT was associated with a signifi-
cant reduction in the ratesofdepressive relapsecomparedwith
usual care or placebo, corresponding to a 34% relative risk re-
duction (risk ratio [RR], 0.66; 95% CI, 0.53-0.82).
Whilewehave a growingbodyof evidencepointing to the
efficacyofMBCT inpreventingdepressive relapses,wedonot
know whether MBCT is differentially efficacious for sub-
groups of people known to be at greater or lesser risk for de-
pressive relapse/recurrence.6,7
Here,wepresentananalysisof individualpatientdata (IPD)
compiled from 9 published randomized trials of MBCT iden-
tified through a systematic literature search. Unlike meta-
analyses of aggregate data at the trial level, IPD analyses per-
mit the investigation of patient-level characteristics thatmay
be potential moderators of treatment effects.8 We examined
theefficacyofMBCTcomparedwithusual care or active treat-
mentgroups forpatients fromarangeof sociodemographicand
psychiatric backgroundsparticipating in studies conducted in
a number of countries in Europe and North America, taking
into account different periods of follow-up across studies.
Methods
The study was conducted in accordance with the Preferred
Reporting Items for Systematic reviews and Meta-Analyses
statement9andthegoodpracticeguidelinesoftheCochraneCol-
laboration IPDMethodsGroup10 (eTable 1 in the Supplement).
Study Identification and Data Extraction
We searched for relevant publications from November 2010
(the searching enddate of thepreviousmeta-analysis,5which
performed searches from the first available date for each da-
tabase) toNovember2014 (Figure 1) using the sameapriori cri-
teria for study inclusion as the previous review, as follows: (1)
Study design: randomized trials of MBCT for the prevention
of relapse in patients with recurrent major depressive disor-
der currently in remission, reported in the English language,
and published or accepted for publication in peer-reviewed
journals; (2) Participants: participants aged 18 years or older,
diagnosedashaving recurrentmajordepressivedisorder in full
or partial remission according to a formal diagnostic classifi-
cation system (major depressive disorderwas defined as a di-
agnosis based on the DSM-III, -III-R, -IV, or -IV-TR or the In-
ternational Statistical Classification of Diseases and Related
Health Problems, Tenth Revision [ICD-10]); (3) Intervention
group: MBCT delivered according to the treatment manual11;
(4) Control group: at least 1 non-MBCT treatment, including
usual care; and (5) Outcome measures: number of partici-
pantsmeeting the diagnostic criteria for a newmajor depres-
sive episode over the follow-up study period, according to
accepted clinical diagnostic criteria such as the ICD-10 or the
DSM-IV-TR.
Studies were identified from searches of titles, abstracts,
and keywords of electronic databases (EMBASE, PubMed/
Medline, PsycINFO, Web of Science, Scopus, and the Coch-
rane Controlled Trials Register) using the following search
string: (mindfulness-based cognitive therapy) OR (mindfulness
Figure 1. Preferred Reporting Items for Systematic Reviews
andMeta-analyses FlowDiagram FromRecord Identification
to Study Inclusion
1789 Reviews, qualitative studies, case
studies, dissertation abstracts,
study protocols, and non-English
articles were excluded
758 Records excluded (did not
meet inclusion criteria)
1 Study excluded because individual
patient data were unavailable
7766 Records identified through
database searching
2555 Records after duplicates removed
766 Records screened against inclusion criteria
8 Full-text articles assessed for eligibility
10 Studies included in qualitative synthesis
9 Studies included in quantitative synthesis
4 Full-text articles excluded
with reasons
6 Studies identified in
previous meta-analysis 5
2 Additional records identified
through other sources
Key Points
Question What is the efficacy of mindfulness-based cognitive
therapy compared with usual care and other treatments?
Findings This individual patient data meta-analysis included 9
trials, comprising 1329 participants. Patients receiving
mindfulness-based cognitive therapy had a significantly reduced
risk of depressive relapse within a 60-week follow-up period
compared with those who received usual care and had comparable
outcomes to those who received other active treatments.
Meaning Mindfulness-based cognitive therapy appears
efficacious as a treatment for relapse prevention for those who
have recurrent depression and provides an alternative choice to
other active treatments.
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based cognitive therapy) OR (MBCT) AND (depress*). No lan-
guage or other limitationswere imposed at this stage.Wealso
checked reference lists of relevant studies and reviews for ad-
ditional references to potentially relevant studies. This pro-
cedure is summarized in Figure 1, and narrative text and an
example of a full search string are provided in eTable 2 in the
Supplement.
Individual patient datawere obtained from the authors of
9of the 10 trialsmeeting the inclusioncriteria andcollated into
1dataset (N = 1329).Overall, IPD integritywas foundtobehigh.
The trials are summarized in Table 1, and data extraction and
cleaning are elaborated on in eTable 3 in the Supplement. Of
the 9 relevant trials, 2 had 3 arms and 7 had 2 arms. One trial
included a placebo pill arm18; this small arm (n = 30) was ex-
cluded from all analyses. The other 3-arm trial23 had 2 non-
MBCT arms: one treatment as usual and the other treatment
asusualwithcognitivepsychological education.For theanaly-
ses of MBCT vs non-MBCT, the 2 non-MBCT arms were com-
bined; for the analyses of MBCT vs an active comparator, the
treatment as usual armwas excluded. We used the Cochrane
risk of bias assessment tool.24 While the risk of bias was gen-
erally low across all trials for most criteria (eTable 4 in the
Supplement), 2 of 9 trials did not blind assessors17,19 and 1 of
these also had incomplete outcome data.17
Primary Outcome
The primary outcome was relapse to depression within 60
weeks of follow-up, collected through a Structured Clinical
Diagnostic Interview.25 For studies with a follow-up beyond
60 weeks, follow-up was censored at 60 weeks. From the 9
trials available, participants with data for relapse status and
time to relapsemeasured inweekswere included in all analy-
ses; if relapsedidnotoccur, time toendof follow-upwasused.
We also reported adverse events.
Sociodemographic and Psychiatric Status Variables
We predefined several sociodemographic characteristics as
potential moderators of the effect of MBCT, ie, sex, age, edu-
cation, relationship status, race/ethnicity, socioeconomic sta-
tus, and employment status. These variables were standard-
ized across the 9 trials using available data to map each
participant to the standardized category (eTable 3 in the
Supplement).
Psychiatric status variables included in the moderator
analyses were severity of depression symptoms at baseline
(measured with the Beck Depression Inventory–II or Inven-
tory of Depressive Symptomatology), baseline mindfulness
measuredon1of several scales, ageatonsetofdepression, and
number of previous major depressive episodes.
Statistical Methods
All statistical analyses were conducted according to partici-
pants’ randomizedallocation in theprimarystudies.Onlycom-
plete case data were included for all trials in the main analy-
ses. In the event of substantive missing data (>10%) for an
individual trial, a sensitivity analysiswasperformedusing im-
puted data based on 2 scenarios—onemaximally favoring the
intervention groupand theothermaximally favoring the con-
trolgroup—for the2-stagemeta-analysiscomparingMBCTwith
non-MBCTonly. All analyseswere performedusing Stata ver-
sion 14 (StataCorp LP).
DoesMBCT Reduce Depressive Relapse/Recurrence
ComparedWith Control Conditions?
Meta-analysesof time-to-eventdatawereused toevaluate the
effect ofMBCTcomparedwithnon-MBCTon theprimaryout-
come. Both 2-stage and 1-stage meta-analysis methods were
used.26 Two-stage methods involved calculating hazard ra-
tios (HRs) fordepressive relapse (MBCTvsnon-MBCT) for each
study individually27,28andusingCoxproportionalhazardmod-
els, and then combining theseHRs in ameta-analysis.Hetero-
geneity was assessed within 2-stage models using the I2
statistic.29A95%CI for the I2 statisticwas calculatedusing the
test-based method.30 Both fixed and random effect(s) mod-
els were applied.31 Meta-analyses were performed on 3 pair-
wise comparisons:MBCT vs all non-MBCT treatments,MBCT
vsactive treatments (antidepressantmedication [ADM]or cog-
nitive psychological education), and MBCT vs ADM only.
For 1-stage meta-analyses, both fixed and random ef-
fect(s) models were applied to the same 3 pairwise compari-
sons. Fixed effect models used the Cox proportional hazards
model to produce an HR; these models included each indi-
vidual studyasastratumwith itsownbaselinehazard.32Where
theproportionalhazardsassumptionwasunsupported,MBCT
status interactingwith log(time)was added to themodel (and
to all subsequent models) to allow the effect of MBCT status
on risk of relapse to vary during the follow-up period. Ran-
domeffects 1-stagemodelsused theStata command stmixed,33
included a study-level randomeffect onMBCTstatus, and ap-
plied a flexible parametric survival model.34
Are the Effects ofMBCT onOutcomesModerated
by Demographic or Depression-Related Variables?
For our primary outcome of depressive relapse, the use of
1-stage meta-analysis models facilitated inclusion of our so-
ciodemographic and depression-related covariates to in-
vestigate moderation.35 The choice of whether to use a fixed
effect or random effects approach would be informed by the
degree of heterogeneity between studies evident from the
2-stage and 1-stage models comparing MBCT with non-
MBCT; in the event of very low heterogeneity, a fixed effect
model would be used. A series of multivariable models were
created, initially including only the MBCT status of the par-
ticipant and 1 additional covariate (the interaction between
MBCT and log[time] was included if appropriate). As a fur-
ther check, all covariates were included in 1 overall model to
establish which were significantly associated with depres-
sive relapse in the presence of all other covariates. Individual
covariates thatwere found to be statistically significant at the
P < .10 threshold in amodel includingMBCT status only or in
amodelwith all covariates combinedwere then included in a
furthermodel. Covariates that did not achieve significance at
the P < .05 level were removed individually from this new
model until the most parsimonious model had been ascer-
tained. Each covariate within thismodel was individually in-
vestigated for interaction with MBCT status (ie, each model
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Table 1. Description of the 9 Primary Studies ofMBCT vs Non-MBCT Treatment
Source; Study Population
and Country
Arm: No. of
Participants
Randomized
Patients With
60-wk Relapse
Status and Time
to Relapse, No.
(%)
Person-wk
Contributed to
Unadjusted
Analyses
Patients With
Final BDI
(Closest
Available to 60
wk)a
Baseline
BDIb, No.,
Mean (SD)
Mindfulness
Measure
Used
Patients With
Pre- and
Posttreatment
Mindfulness
Scorea SAEs/SARs
Teasdale et al,7 2000;
Community adults with
history of depression,
currently in full remission,
not receiving ADM at
assessment;
United Kingdom and
Canada
TAU: 69;
MBCT: 76
Non-MBCT:
66 (96);
MBCT: 70 (92);
total % missing: 6
Non-MBCT:
2363;
MBCT: 3093
Non-MBCT: 65;
MBCT: 65
132,
11.4 (7.9)
EQ12 Non-MBCT:
12;
MBCT: 14
Not formally
recorded
Ma and Teasdale,6 2004;
Community adults with
history of depression,
currently in full remission,
not receiving ADM at
assessment;
United Kingdom
TAU: 38;
MBCT: 37
Non-MBCT:
37 (97);
MBCT: 36 (97);
total % missing: 3
Non-MBCT:
1237;
MBCT: 1770
Non-MBCT: 33;
MBCT: 34
73,
13.9 (8.4)
EQ12 Non-MBCT:
31;
MBCT: 32
Not formally
recorded
Kuyken et al,13 2008;
Community adults with
history of ≥3 episodes of
depression, currently in
remission, receiving ADM;
United Kingdom
ADM: 62;
MBCT: 61
Non-MBCT:
62 (100);
MBCT: 61 (100)
Non-MBCT:
2271;
MBCT: 2592
Non-MBCT: 58;
MBCT: 59
123,
19.3 (11.9)
KIMS14 Non-MBCT:
58;
MBCT: 55
No SARs in either
arm
Bondolfi et al,15 2010;
Community adults with
history of ≥3episodes of
depression, currently in
remission, not receiving
ADM at assessment;
Switzerland
TAU: 29;
MBCT: 31
Non-MBCT:
29 (100);
MBCT: 31 (100)
Non-MBCT:
1205;
MBCT: 1386
Non-MBCT: 26;
MBCT: 26
60,
9.9 (9.0)
MAAS16 Non-MBCT:
29;
MBCT: 28
Not formally
recorded; author
communication
that none was
recorded
Godfrin and van
Heeringen,17 2010;
Community adults with
history of ≥3episodes of
depression, currently in
remission, both receiving
and not receiving ADM at
assessment;
Belgium
TAU: 54;
MBCT: 52
Non-MBCT:
47 (87);
MBCT: 40 (77);
total % missing:
18
Non-MBCT:
1690;
MBCT: 1964
Non-MBCT: 40;
MBCT: 35
86,
19.9 (12.2)
MAAS16 Non-MBCT:
47;
MBCT: 37
Not formally
recorded
Segal et al,18 2010c; At
point of randomization to
MBCT, community adults
with history of depression,
currently in full remission
after 8 mo of
algorithm-informed ADM in
an earlier study phase;
Canada
Maintenance
ADM: 28;
MBCT after
discontinued
ADM: 26
Non-MBCT:
28 (100);
MBCT: 26 (100)
Non-MBCT:
1002;
MBCT: 1007
Non-MBCT: 7;
MBCT: 11
51,
4.0 (3.9)
MAAS16 Non-MBCT:
10;
MBCT: 15
1 SAE in acute
phase (ADM arm)
and in the
follow-up phase;
0 SAEs in either
arm of the trial
Huijbers et al,39 2012, and
Huijbers et al,19 2015d;
Community adults with
history of ≥3 episodes of
depression, currently in
remission, receiving ADM;
The
Netherlands
Maintenance
ADM: 35;
MBCT and
ADM: 33
Maintenance
ADM: 35 (100);
MBCT and ADM:
33 (100)
Non-MBCT:
1342;
MBCT: 1433
Non-MBCT: 28;
MBCT: 28
68,
12.1 (9.6)
FFMQ20 Non-MBCT:
27;
MBCT: 26
No SARs in either
arm
Kuyken et al,21 2015;
Community adults with
history of ≥3 episodes of
depression, currently in
remission, receiving ADM;
United Kingdom
Maintenance
ADM: 212;
MBCT and
discontinued
ADM: 212
Maintenance
ADM: 202 (95);
MBCT and
discontinued
ADM: 200 (94);
total % missing: 5
Non-MBCT:
8882;
MBCT: 9471
Non-MBCT:
157;
MBCT: 167
396,
14.1 (10.2)
FFMQ22 Non-MBCT:
169;
MBCT: 173
10 SAEs (5 MBCT
arm; 5 in ADM
arm), none of
which were
judged as SAR
Williams et al,23 2014;
Community adults with
history of ≥3 episodes of
depression, currently in
remission, receiving ADM;
United Kingdom
TAU: 56;
CPE: 110;
MBCT: 108
TAU: 53 (95);
CPE: 103 (94);
MBCT: 99 (92);
total % missing: 7
Non-MBCT:
6022;
MBCT: 4199
Non-MBCT:
135;
MBCT: 88
255,
8.0 (7.8)
FFMQ22 Non-MBCT:
138;
MBCT: 87
15 SAEs (5 MBCT
arm; 10 in CPE
arm), of which
1 (CPE) was
judged as SAR
Abbreviations: ADM, antidepressant medication; BDI, Beck Depression
Inventory; CPE, cognitive psychological education; EQ, Experiences
Questionnaire; FFMQ, Five Facet Mindfulness Questionnaire; KIMS, Kentucky
Inventory of Mindfulness Scale; MAAS, Mindful Attention Awareness Scale;
MBCT, mindfulness-based cognitive therapy; SAEs, serious adverse events;
SARs, serious adverse reactions; TAU, treatment as usual.
a Primary outcome data available.
b Includes all participants irrespective of trial arm.
c Placebo arm excluded.
dHuijbers et al19 used Inventory of Depressive Symptomatology
(Clinician-Rated).
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includedonly 1 interaction term), andany thatwerenot found
to be a significant predictor of time to relapse were individu-
ally included in the model with all other significant predic-
tors to investigate potential interaction with MBCT status. In
addition, moderation effects between each MBCT status and
each individual covariatewere investigated in a series ofmod-
els including only MBCT status, the specified covariate, and
their interaction.
Results
Description of Primary Studies
The 9 included studies are described fully in the original trial
reports and are summarized here in Table 1. We defined loss
to follow-up as a lack of data on relapse status after 60weeks
(or closest available time) of follow-up. Of the 1329 random-
ized participants from the 9 trials with available IPD, data on
relapse status and time to relapse (or endof follow-upwithno
relapse) were available for 1258 participants (94.7%). Across
the sample of 1258 participants, the mean (SD) age was 47.1
(11.9) years (median, 47 years; interquartile range, 39-56), and
944 (75.0%)were female.Of 1230participantswithdata avail-
able, 509 (41.4%) had at least degree-level qualifications, 636
(51.7%) had qualifications below degree level, and 85 (6.9%)
had no qualifications. Of 1239 participants, 726 (58.6%) were
married or had a partner, 234 (18.9%) were single, and 279
(22.5%) were divorced, separated, or widowed. Among 1234
participants, themean(SD)ageatonsetofdepressionswas26.0
(12.2) years (median, 23 years; interquartile range, 17-34), and
of 1200 participants, 694 (57.8%) had 5 or more past depres-
siveepisodes.Within individual studies, theproportionofpar-
ticipants lost to follow-up ranged from0%to 18% (Table 1). Of
596participantswho receivedMBCT, 229 (38%)hadadepres-
sive relapse within 60 weeks’ follow-up, whereas 327 of 662
participants (49%) who did not receive MBCT had a depres-
sive relapse within 60 weeks.
DoesMBCT Reduce Depressive Relapse Compared
With Control Conditions?
Owing to clinical heterogeneity across the 9 studies, the re-
sultsof therandomeffectsmodelsare reported;becauseofvery
low heterogeneity of treatment effects between studies, the
results of equivalent fixed effect analyses were very similar.
A forest plot of the 2-stagemeta-analysis of time to relapse of
depression compared MBCT with all non-MBCT treatments
(HR, 0.69; 95% CI, 0.58-0.82; I2, 1.7%; 95% CI, 0-20)
(Figure 2A). The funnel plot associated with this analysis in-
dicated some asymmetry, with an absence of smaller studies
that showed an increased risk of relapse with MBCT treat-
ment (eFigure 1 in the Supplement). The associatedEgger test
produced a P value of .18, although we recognize the limited
power of this test with only 9 studies. A sensitivity analysis
whereby missing outcome data from Godfrin and van
Heeringen17 were imputed favoring the MBCT group pro-
duced anHR of 0.63 (95%CI, 0.49-0.82); using imputed data
that favored thenon-MBCTgroupproducedanHRof0.74 (95%
CI, 0.63-0.88). An equivalent analysis comparingMBCTwith
all active treatments was conducted using data from 5
studies13,18,19,21,23 (HR, 0.79; 95% CI, 0.64-0.97; I2, 0%)
(Figure 2B). An analysis comparing MBCT with ADM treat-
ment was conducted using data from 4 studies13,18,19,21 (HR,
0.77; 95% CI, 0.60-0.98; I2, 0%) (Figure 2C). For the latter 2
meta-analyses, the I2 value was 0% in both cases, the lower
boundary of the 95% CI was 0%, and the upper boundaries
were 43% and 65%, respectively.
An unadjusted 1-stage fixed effect meta-analysis com-
paredMBCTwithnon-MBCTtreatment (1248patients, 554de-
pressive relapses within 60 weeks; HR, 0.69; 95% CI, 0.58-
0.82) (Table2,modelA).However, evidence indicated that the
proportional hazards assumption was not valid (eFigure 2 in
the Supplement shows the log-log plots comparing theMBCT
and non-MBCT groups for each of the 9 included studies).
Owing to the lack of proportional hazards, the interaction be-
tween MBCT status and log(time) was added, allowing the
effects of MBCT to vary with log(time). This model (Table 2,
model B) yielded anHR forMBCTof0.34 (95%CI, 0.19-0.60),
and for the interaction of MBCT with log(time) of 1.28 (95%
CI, 1.06-1.55), thismodel indicated a reduction in the preven-
tive effect of MBCT on depressive relapse as time progressed
during the follow-up period.
A 1-stage fixedeffectmodelusing5 studies13,18,19,21,23 com-
paredMBCTwithactive treatmentsonly (892participants and
385 relapses; HR, 0.78; 95% CI, 0.64-0.96) (Table 2, model C)
andwasverysimilar tothe2-stagerandomeffectsmodel,which
providedlittleevidenceto indicate lackofproportionalhazards.
Theequivalent analysis comparingMBCTwithADMtreatment
used4 studies13,18,19,21 (637participants and266 relapses;HR,
0.77; 95%CI, 0.60-0.98) (Table 2,model D) andwas identical
totheresultsof the2-stagerandomeffectsmodel,alsowith little
evidence to support lack of proportional hazards.
The 1-stage randomeffectsmodel comparedMBCTwithall
non-MBCT treatments using a flexible parametric model with
2 df (HR, 0.68; 95%CI, 0.58-0.81; between-study SD, 0.0008)
(Table2,modelE).A furthermodel comparingMBCTwithnon-
MBCTwascreatedbyaddingthe interactionbetweenMBCTsta-
tus and the restricted cubic splines derived from the previous
model (HR,0.63;95%CI,0.53-0.76;between-studySD,0.0007)
(Table 2, model F); the global P value for the interaction be-
tween MBCT status and each restricted cubic spline was .04,
consistent with a significant time-varying effect of MBCT
status observed in the fixed effect model.
Equivalent analyses comparingMBCTwithall active treat-
mentsandcomparingMBCTwithADM,withorwithouta time-
varying effect on MBCT status, failed to converge, almost
certainly owing to very low heterogeneity between studies.
Are the Effects ofMBCT onOutcomesModerated
by Demographic and Depression-Related Variables?
In viewof the lowheterogeneity between studies, fixed effect
1-stagemodelswereusedforthemoderationanalyses. Individu-
ally, 5 sociodemographic andpsychiatric variableswere found
to be significantly associated with risk of relapse within 60
weeks:baselinedepressionzscore,baselinemindfulnesszscore,
age at onset, number of previous episodes, andmarital status
(allP < .10).With theexceptionofmarital status, all of theseco-
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variateswere also significantly associatedwith time to relapse
when included inamodelwithMBCTstatusand its interaction
withlog(time)andallothercovariates.Whenincludedinamodel
withMBCT status and its interactionwith log(time), only 4 re-
mainedstatisticallysignificant:baselinedepressionzscore,base-
linemindfulness z score, age at onset, andnumberof previous
episodes. However, on including these 4 covariates, the inter-
action betweenMBCT status and log(time) was no longer sig-
nificant (P = .052), so itwas removedfromthemodel.Thus, the
significantpredictorsofdepressiverelapsewerebaselinedepres-
sionzscore,baselinemindfulnesszscore,ageatonset,andnum-
ber of previous episodes.When including the interactionwith
MBCT and each predictor in turn into thismodel, baseline de-
pression z scorehada significant interactionwithMBCTstatus
(Table2,modelG;Figure3); patientswithahigherbaselinede-
pression z score received greater benefit from MBCT therapy
comparedwithallnon-MBCTtreatments.Of the remainingsig-
nificant covariates, onlybaselinemindfulness z scorehadasig-
nificant interactionwithMBCT status both in amodelwith no
other covariates and inamodelwithall other significant covar-
iates.However, these interactionsbecamenonsignificantwhen
the interactionbetweenMBCT status andbaseline depression
z scorewasaddedto themodel.Noothercovariateswere found
tohaveasignificant interactionwithMBCTstatuswhenincluded
inamodelwithallothersignificantcovariatesor inamodelwith
onlytherespectivecovariate,MBCTstatus, their interaction,and
the interaction betweenMBCT status and log(time).
Discussion
Summary of Results
Replicatingpreviouswork,we foundclearevidence thatMBCT
was associated with a significant reduction in the risk of
Figure 2. RandomEffectsMeta-analyses ComparingMindfulness-Based Cognitive Therapy (MBCT)With Other
Variables
Weight, %Study
Hazard Ratio
(95% CI)
12.8Teasdale et al,7 2000 0.64 (0.40-1.03)
6.5Ma and Teasdale,6 2004 0.45 (0.23-0.88)
11.6Kuyken et al,13 2008 0.66 (0.40-1.08)
3.6Bondolfi et al,15 2010 0.77 (0.31-1.90)
6.6Godfrin and van Heeringen,17 2010 0.34 (0.17-0.66)
5.6Segal et al,18 2010 0.74 (0.36-1.52)
4.5Huijbers et al,19 2015 0.80 (0.36-1.78)
28.4Kuyken et al,21 2015 0.81 (0.59-1.10)
20.4Williams et al,23 2014 0.82 (0.57-1.20)
100Overall (I2 = 1.7%, P = .42) 0.69 (0.58-0.82)
MBCT vs no MBCTA
Weight, %Study
Hazard Ratio
(95% CI)
17.4Kuyken et al,13 2008 0.66 (0.40-1.08)
6.4Segal et al,18 2010 0.80 (0.35-1.82)
6.7Huijbers et al,19 2015 0.80 (0.36-1.78)
43.7Kuyken et al,21 2015 0.81 (0.59-1.11)
25.8Williams et al,23 2014 0.85 (0.56-1.28)
100Overall (I2 = 0.0%, P = .96) 0.79 (0.64-0.97)
MBCT vs any active treatmentB
Weight, %Study
Hazard Ratio
(95% CI)
23.4Kuyken et al,13 2008 0.66 (0.40-1.08)
8.6Segal et al,18 2010 0.80 (0.35-1.82)
9.1Huijbers et al,19 2015 0.80 (0.36-1.78)
58.9Kuyken et al,21 2015 0.81 (0.59-1.11)
100Overall (I2 = 0.0%, P = .92) 0.77 (0.60-0.98)
MBCT vs antidepressantsC
1.0 2.00.1 0.5
0.5
0.5
Hazard Ratio (95% CI)
1.0 2.00.1
Hazard Ratio (95% CI)
1.0 2.00.1
Hazard Ratio (95% CI)
Forest plot of 2-stagemeta-analysis
of aggregate data on hazard ratio
scale comparing (A) risk of relapse of
depression in participants receiving
MBCTwith participants not receiving
MBCT; (B) risk of relapse of
depression in participants receiving
MBCTwith participants receiving an
alternative active therapy;
and (C) risk of relapse of depression
in participants receiving MBCTwith
participants receiving antidepressant
medication. Weights are from
random effects analyses.
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depressive relapse/recurrence over 60weeks compared with
usual care. Extendingpreviouswork,we found thatMBCT re-
duces the riskofdepressive relapse/recurrencecomparedwith
the current mainstay approach, maintenance antidepres-
sants. We further showed that there is no support for MBCT
havingdifferential effects for patients basedon their sex, age,
education, or relationship status, suggesting the interven-
tion’s generalizability across thesecharacteristics.Different re-
search groups conducted the 9 randomized clinical trials and
useddifferent clinicians across a rangeofEuropeanandNorth
American countries. The lack of heterogeneity between stud-
ies in effects on time to depressive relapse suggests that the
effects of MBCT are similar in these different contexts.
Mindfulness-basedcognitivetherapywasdevelopedforpa-
tients in remission but at high risk for depressive relapse/
recurrence. Our analyses suggest that the treatment effect of
MBCT on the risk of depressive relapse/recurrence is larger in
participantswithhigher levelsofdepressionsymptomsatbase-
line compared with non-MBCT treatments, suggesting that
MBCT may be particularly helpful to those who still have sig-
nificant depressive symptoms. This is consistent with several
recent trials thatsuggestMBCTmaybemoreeffectiveforpeople
whosedepressivesymptomsfluctuate18and/orwhoreportahis-
tory of early adversity.21,23 Adverse events were formally re-
corded in 6 of 9 studies, but nonewere attributed toMBCT.
Strengths and Limitations of the Study
To address the question of whether treatment effects are
influencedby individual patient characteristics, a studyneeds
to be adequately powered and use appropriate statistical ap-
proaches.Within theconstraintsof theconstituent studies,our
IPD approach provided an opportunity to answer these ques-
tions.Riskofbiaswas low, suggestingconfidence in these find-
ings. Combining a series ofmodest-sized trials with effects in
the predicted direction but missing significance individually
yields a significant combined estimate of effect.
We did observe asymmetry in the funnel plot with an ab-
sence of smaller studies that showed an increased risk of
Table 2. Cox Proportional Hazards RegressionModels and Flexible Parametric Survival Models
Covariate No. HR (95% CI) P Value
Model Aa
Participants 1248 NA NA
Depressive relapses 554 NA NA
MBCT status (reference: non-MBCT) NA 0.69 (0.58-0.82) <.001
Model Ba
Participants 1248 NA NA
Depressive relapses 554 NA NA
MBCT status (reference: non-MBCT) NA 0.34 (0.19-0.60) <.001
MBCT by log(time)b NA 1.28 (1.06-1.55) .01
Model Ca
Participants 892 NA NA
Depressive relapses 385 NA NA
MBCT status (reference: active treatments) NA 0.78 (0.64-0.96) .02
Model Da
Participants 637 NA NA
Depressive relapses 266 NA NA
MBCT status (reference: antidepressant medication) NA 0.77 (0.60-0.98) .03
Model Ec
Participants 1248 NA NA
Depressive relapses 554 NA NA
Between-study SD 0.0008 NA NA
MBCT status (reference: non-MBCT) NA 0.68 (0.58-0.81) <.001
Model Fd
Participants 1248 NA NA
Depressive relapses 554 NA NA
Between-study SD 0.0007 NA NA
MBCT status (reference: non-MBCT) NA 0.63 (0.53-0.76) <.001
Model Ga,e
Participants 1022 NA NA
Depressive relapses 443 NA NA
MBCT status (reference: non-MBCT) NA 0.74 (0.61-0.90) .003
Baseline depression score NA 1.40 (1.24-1.58) <.001
Baseline depression score by MBCT status NA 0.80 (0.66-0.97) .02
Abbreviations: HR, hazard ratio;
MBCT, mindfulness-based cognitive
therapy; NA, not applicable.
a Cox proportional hazards regression
model stratified by individual study.
b Timemeasured in weeks.
c Flexible parametric model with 2 df
and random treatment effects.
dBased onmodel E, with the
inclusion of interaction between
MBCT status and restricted cubic
splines to account for the
time-varying effect of MBCT
(P = .04).
e Model adjusted for baseline
mindfulness z score, age at onset of
depression, and number of past
episodes of depression (5 or more/4
or fewer).
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relapse withMBCT treatment. It is possible that there are un-
published studies that we are not aware of, and we welcome
investigators of any such studies to bring them to our atten-
tion so that their data can be included in future updates. The
unavailability of the Meadows et al36 study data represents
an impediment to IPD, transparency, and external scrutiny.
Funding bodies, ethics committees, and sponsors should
work to a consensus position. Finally, allegiance effects can
influence effect sizes in psychological therapy trials,37 and
the constituent trials were largely conducted by proponents
of MBCT. Therefore, we analyzed risk of bias (eTable 4 in the
Supplement).
There were a number of limitations resulting from avail-
ability of datawithin the constituent studies. For example,we
were not able to obtain information about important poten-
tialmoderators suchas race/ethnicity andemployment. Trials
alsovary in thewaydata are collected.For example, ageat first
onset ofdepressionwas collected in some trials by simple self-
report and in others through standardized Structured Clini-
cal Interview. Number of prior episodeswas also gathered in-
consistently.Adverse eventswerenot systematically recorded
or reported.Aswithallmeta-analyses, theremaybe trialspub-
lished inother languagesorunpublishedtrialswewerenotable
to access.Moderator analyseswerenot formally powered, ex-
ploratory, or relatively large in number, increasing the risk of
type I errors. Future studies should plan and power for mod-
erator analyses.
Conclusions
While previous research has shown the superiority of MBCT
comparedwithusual care,5 this studyprovides importantnew
evidence thatMBCT is also effective comparedwith other ac-
tive treatments and that its effects are not restricted to par-
ticular groups defined by age, educational level, marital sta-
tus, or sex. A recentmeta-analysis38 of the effectiveness of all
psychological interventions to prevent recurrence compared
with usual care and antidepressants suggests that the protec-
tive effects of MBCT are comparable with those for cognitive
therapy (vs usual care: RR, 0.68; 95% CI, 0.54-0.87; vs ADM:
RR,0.08;95%CI,0.61-1.02)and interpersonal therapy (vsusual
care: RR, 0.41; 95% CI, 0.27-0.63; vs ADM: RR, 0.08; 95% CI,
0.50-1.38).However,MBCTaddressesaparticular clinicalprob-
lem,namely teachingskills to staywell topeoplecurrentlywell
but at high risk of depressive relapse. There is a reduction in
protective effects over time. The finding that MBCT may be
mosthelpful forpatientswithhigher levelsofdepressivesymp-
toms adds to an emerging consensus that the greater the risk
for depressive relapse/recurrence, themore benefitMBCTof-
fers. Patients with lower baseline scores appeared to receive
less benefit but were not disadvantaged by MBCT.
We recommend that future trials consider an active
control group, use comparable primary and secondary out-
comes (Structured Clinical Interview for DSM for depressive
relapse), use longer follow-ups, report treatment fidelity,
collect key background variables (eg, race/ethnicity and
employment), take care to ensure generalizability, conduct
cost-effectiveness analyses, put in place ethical and data
man-agement procedures that enable data sharing, consider
mechanisms of action, and systematically record and report
adverse events.
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